CastleArk Alternatives’s Repligen RGEN Stock Holding History

CastleArk Alternatives’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,470	Closed	-$425K	–	226
2021 Q3	$425K	Buy	+1,470	New	+$377K	0.02%	260

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CastleArk Alternatives's RGEN Position: Q4 2021 in Review

CastleArk Alternatives sold out of Repligen (RGEN) in Q4 2021, closing a stake of 1,470 shares — an estimated $425K sold.

CastleArk Alternatives first reported a position in RGEN in Q3 2021 and held it in 1 quarter. The position peaked at $425K in Q3 2021. 507 funds tracked by Wall St. Rank hold RGEN as of Q4 2021.

CastleArk Alternatives reported no remaining Repligen position as of Q4 2021 after selling out during the quarter.
CastleArk Alternatives sold 1,470 Repligen shares in Q4 2021, an estimated $425K.
CastleArk Alternatives first reported a position in Repligen in Q3 2021 and held it in 1 quarter.
CastleArk Alternatives's Repligen position peaked at $425K in Q3 2021.
507 funds tracked by Wall St. Rank held Repligen as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.